At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Seasonal Influenza Vaccine (MF59C.1)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects
In Brief
A Phase 2 clinical trial evaluating Seasonal Influenza Vaccine (MF59C.1) for Seasonal Influenza. Completed, enrolled 63 participants across 2 sites.
Detailed Summary
This is a trial for annual registration of the updated seasonal influenza vaccine formulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Influenza
CountriesItaly
CollaboratorsNovartis Vaccines
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
Primary CompletionJun 2009
First PostedAug 2009
TodayJul 2026
First PostedAug 11, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 16.9 years ago
Interventions
Seasonal Influenza Vaccine (MF59C.1)biological
1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010